ARTICLE | Clinical News
GamaMabs reports Phase I data for GM102 in gynecological cancers
June 1, 2018 6:05 PM UTC
GamaMabs Pharma S.A. (Toulouse, France) reported data from four evaluable patients with granulosa ovarian cancer in the Phase Ia/Ib C101 trial showing that GM102 led to two partial responses. GM102 was well tolerated with no dose-limiting toxicities (DLTs) reported. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago...
BCIQ Target Profiles